A Russian company specialized in production of chitosan gel with venom of an adder and pharmaceutical substance based on snake venom, is looking for trade intermediaries, dealers and partners for joint venture. Main company’s products: snake venom, derivatives of snake venom, chitosan gel with snake venom. Products are used for relief of pain caused by muscles straining, injury, or trauma. Envisaged cooperation is in form of distribution, commercial agency and joint-venture agreement.
Russian company is specialized in production of chitosan gel with venom of an adder and pharmaceutical substance based on snake venom, is looking for trade intermediary services (agent, representative, distributor) and partners for joint venture. Trade intermediaries are trade companies, which will buy chitosan gel and pharmaceutical substance and sale it. Partners for joint venture are pharmaceutical plants or R&D institutions. Company will supply pharmaceutical substance based on snake venom to pharmaceutical plant, which will buy it. Than company and plant can jointly develop new product and produce it on pharmaceutical plant. company can develop new products with R&D institution too. The company was established in 2005. The company has already engaged in international cooperation, with snake venom being supplied to EU pharmaceutical factories, today it tries to enter new markets.
Innovations and advantages
1. Company is the only producer of venom of an adder (Vipera berus) in Russia and the biggest producer in the world. Company’s product is registered in Russia as a pharmaceutical substance, used in Russia and exported abroad. 2. Company implements the whole manufacturing cycle: breeding of an adder in special serpentarium, production of dry poison, quality control in own analytical laboratory. 3. More than 20 years of work experience of main specialists (herpetologists). 4. High effectiveness of company’s production: receipt of big quantity of poison from one snake and increasing life span of snake allow for manufacture of bigger capacity of poison from fewer numbers of snakes. 5. In 2014 company with its partner developed the first product for final consumer - chitosan gel with venom of an adder. This gel doesn’t have analogs on the market: it’s the first gel of external remedy with snake’s poison. In addition gel has an optimally selected dosage of poison - 4 mg / 100 g of gel. This dosage is higher than other analogs have. Chitosan supramolecular particles provide transdermal delivery of poison component to pain localization.
Market application codes
05007002 Pharmaceuticals/fine chemicals
07004002 Health and beauty aids
Intellectual property rights
Other (registered design, plant variety, etc)
Area of partner's activity
Potential partners are: 1. Trade companies, which will buy chitosan gel and pharmaceutical substance and sale it: - pharmacies; - pharmaceutical distributors; - fitness-centres; - medical centres. 2. Pharmaceutical plants, producers of cosmetics. Company will supply pharmaceutical substance based on snake venom to plant, which will buy it. Than company and plant develop new product and produce it on pharmaceutical plant. 3. R&D institutions: development of new products with the company.